Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Costa, Daniel
Item TypeName
Academic Article Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.
Academic Article Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
Academic Article Serum concentrations of Erlotinib at a dose of 25 mg daily.
Academic Article More than just an oncogene translocation and a kinase inhibitor: Kevin's story.
Academic Article Erlotinib-associated alopecia in a lung cancer patient.
Academic Article Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
Academic Article Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
Academic Article Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Academic Article CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.
Academic Article Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.
Academic Article EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.
Academic Article EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.
Academic Article Gefitinib plus docetaxel in non-small-cell lung cancer.
Academic Article Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer.
Academic Article Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Academic Article The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
Academic Article Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Academic Article Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Academic Article Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
Academic Article Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
Academic Article BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
Concept Protein Kinase Inhibitors
Academic Article Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.
Academic Article Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Academic Article Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.
Academic Article Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.
Academic Article Management and future directions in non-small cell lung cancer with known activating mutations.
Academic Article EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients.
Academic Article Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Academic Article Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
Academic Article RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Academic Article Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
Academic Article In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.
Academic Article Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
Academic Article Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
Academic Article Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.
Academic Article The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.
Academic Article ALK inhibitors: plateauing systemic and intracranial activity?
Academic Article Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.
Academic Article A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Academic Article Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial.
Academic Article De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.
Academic Article Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?
Academic Article Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
Academic Article Ascending role of next-generation ALK inhibitors.
Academic Article Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.
Academic Article De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.
Academic Article Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer.
Academic Article Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.
Academic Article EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.
Academic Article SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Academic Article Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
Search Criteria
  • Protein Kinase Inhibitors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.